A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer

Trial Profile

A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Oct 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 02 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top